TIAPROFENIC ACID

Details

Stereochemistry	RACEMIC
Molecular Formula	C14H12O3S
Molecular Weight	260.308
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C(O)=O)C1=CC=C(S1)C(=O)C2=CC=CC=C2

InChI

InChIKey=GUHPRPJDBZHYCJ-UHFFFAOYSA-N

InChI=1S/C14H12O3S/c1-9(14(16)17)11-7-8-12(18-11)13(15)10-5-3-2-4-6-10/h2-9H,1H3,(H,16,17)

HIDE SMILES / InChI

Molecular Formula	C14H12O3S
Molecular Weight	260.308
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://mein.sanofi.de/produkte/Surgam/Downloads?id=d7a43169-0340-476a-a43c-1871c227d63b

Tiaprofenic acid is a non-steroidal, anti-inflammatory, analgesic compound, which nonselectively inhibits cyclooxygenase protein. Tiaprofenic acid was approved in Europe for the symptomatic relief of arthritis, ankylosing spondylitis and other inflammatory-rheumatic disorders as well as the painful conditions after injury.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Cyclooxygenase 89 Target ID: CHEMBL2094253 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17652824	Inhibitor 8297

Conditions

Condition	Modality	Highest Phase	Product
Arthritis 89 Sources: https://mein.sanofi.de/produkte/Surgam/Downloads?id=d7a43169-0340-476a-a43c-1871c227d63b	Palliative	Approved 8429	SURGAM Approved Use Symptomatic treatment of pain and inflammation in acute arthritis (including gout attack), chronic arthritis (rheumatoid arthritis in particular), ankylosing spondylitis and other inflammatory-rheumatic spinal disorders, irritation in degenerative joint and spine diseases (arthritis and spondylarthritis), inflammatory soft tissue rheumatic diseases, painful swelling or inflammation after injury.
Pain after injury 2 Sources: https://mein.sanofi.de/produkte/Surgam/Downloads?id=d7a43169-0340-476a-a43c-1871c227d63b	Primary	Approved 8429	SURGAM Approved Use Symptomatic treatment of pain and inflammation in acute arthritis (including gout attack), chronic arthritis (rheumatoid arthritis in particular), ankylosing spondylitis and other inflammatory-rheumatic spinal disorders, irritation in degenerative joint and spine diseases (arthritis and spondylarthritis), inflammatory soft tissue rheumatic diseases, painful swelling or inflammation after injury.
Soft-tissue rheumatic conditions 2 Sources: https://mein.sanofi.de/produkte/Surgam/Downloads?id=d7a43169-0340-476a-a43c-1871c227d63b	Palliative	Approved 8429	SURGAM Approved Use Symptomatic treatment of pain and inflammation in acute arthritis (including gout attack), chronic arthritis (rheumatoid arthritis in particular), ankylosing spondylitis and other inflammatory-rheumatic spinal disorders, irritation in degenerative joint and spine diseases (arthritis and spondylarthritis), inflammatory soft tissue rheumatic diseases, painful swelling or inflammation after injury.

PubMed

Title	Date	PubMed
Directed control of electroosmotic flow in nonaqueous electrolytes using poly(ethylene glycol) coated capillaries.	2001	11296921
In vitro effects of NSAIDS and paracetamol on oxidative stress-related parameters of human erythrocytes.	2001 Jun	11484831
Screening procedure for detection of non-steroidal anti-inflammatory drugs and their metabolites in urine as part of a systematic toxicological analysis procedure for acidic drugs and poisons by gas chromatography-mass spectrometry after extractive methylation.	2001 May-Jun	11386636
Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients.	2001 Nov	11792017
Differential effects of nonsteroidal antiinflammatory drugs on the IL-1 altered expression of plasminogen activators and plasminogen activator inhibitor-1 by articular chondrocytes.	2002 Aug	12234061
[Cross-reaction potentials of ketoprofen].	2002 May 12	12063858
[Photocontact dermatitis due to ketoprofen and photosensitization to tetrachlorosalicylanide and to Fenticlor(R)].	2002 Oct	12442124
Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study.	2003 Jun 2	12771981
Evaluation of balhimycin as a chiral selector for enantioresolution by capillary electrophoresis.	2004 Aug	15351999
Vehicle effects on in vitro release of tiaprofenic acid from different topical formulations.	2004 Jul	15231433
Nitric oxide and cardiovascular effects: new insights in the role of nitric oxide for the management of osteoarthritis.	2008	19007428

Patents

Sample Use Guides

In Vivo Use Guide

The recommended daily dose range for adults is 600 mg tiaprofen acid per day divided into 2 doses.

Route of Administration: Oral

In Vitro Use Guide

Human osteoarthritic cartilage was treated with therapeutic doses of tiaprofenic acid (26 micrograms/ml; 2.6 micrograms/ml) in order to test the effect of the drug on the proteoglycan metabolism (catabolism and synthesis) and chondrocyte ultrastructure. The drug suppresed the proteoglycan metabolism by 38%.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:30:44 GMT 2023` Edited by `admin` on `Fri Dec 15 15:30:44 GMT 2023`
Record UNII	1LS1T6R34C
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TIAPROFENIC ACID

Official Name

English

TIAPROFEN

Brand Name

English

SURGAM

Brand Name

English

Tiaprofenic acid [WHO-DD]

Common Name

English

TIAPROFENATE

Common Name

English

tiaprofenic acid [INN]

Common Name

English

5-BENZOYL-.ALPHA.-METHYL-2-THIOPHENEACETIC ACID

Systematic Name

English

TIAPROFENIC ACID [MI]

Common Name

English

RU-15060

Code

English

TIAPROFENIC ACID [MART.]

Common Name

English

TIAPROFENIC ACID [JAN]

Common Name

English

TIAPROFENIC ACID [EP IMPURITY]

Common Name

English

TIAPROFENIC ACID [EP MONOGRAPH]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QM01AE11